LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.
Computed tomography
Hepatocellular carcinoma
Magnetic resonance imaging
Response Evaluation Criteria In Solid Tumors
Therapeutic chemoembolization
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
30
11
2020
accepted:
05
03
2021
revised:
17
02
2021
pubmed:
24
3
2021
medline:
3
8
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
To evaluate the inter-reader reproducibility and prognostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (LR-TR) at the time of initial post-treatment evaluation following drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC). This retrospective study included patients with HCC who underwent first-line DEB-TACE between January 2011 and December 2015. Six readers (three fellowship-trained radiologists and three radiology trainees) independently assessed lesion-level response in up to two treated lesions per LR-TR and modified Response Evaluation Criteria in Solid Tumors (mRECIST)-target criteria, as well as patient-level response per mRECIST-overall criteria, on the initial post-treatment CT/MRI. Inter-reader agreement was calculated by Fleiss' multi-reader κ. We tested whether LR-TR, mRECIST-target, and mRECIST-overall response were associated with overall survival using Kaplan-Meier and Cox proportional hazard model analyses. A total of 82 patients with 113 treated target lesions were included. Inter-reader agreement was moderate for LR-TR and mRECIST-overall (κ range 0.42-0.57), and substantial for mRECIST-target (κ range 0.62-0.66), among all three reader-groups: all readers, experienced readers, and less-experienced readers. LR-TR and mRECIST-target response were not significantly associated with overall survival regardless of reader experience (P > 0.05). In contrast, mRECIST-overall response was significantly associated with overall survival when assessed by all readers (P = 0.02) and experienced readers (P = 0.03), but not by the less-experienced readers (P = 0.35). Although LR-TR algorithm has moderate inter-reader reproducibility, it alone may not predict overall survival on the initial post-treatment CT/MRI after first-line DEB-TACE for HCC.
Identifiants
pubmed: 33755735
doi: 10.1007/s00261-021-03043-6
pii: 10.1007/s00261-021-03043-6
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3708-3716Subventions
Organisme : NIH HHS
ID : U01 C230694
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, Schirmacher P, Vilgrain V (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69 (1):182-236. https://doi.org/10.1016/j.jhep.2018.03.019
doi: 10.1016/j.jhep.2018.03.019
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68 (2):723-750. https://doi.org/10.1002/hep.29913
doi: 10.1002/hep.29913
pubmed: 29624699
Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han K-H, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen P-J, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK (2017) Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11 (4):317-370. https://doi.org/10.1007/s12072-017-9799-9
doi: 10.1007/s12072-017-9799-9
pubmed: 28620797
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R (2010) Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovasc Intervent Radiol 33 (1):41-52. https://doi.org/10.1007/s00270-009-9711-7
doi: 10.1007/s00270-009-9711-7
pubmed: 19908093
Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 46 (3):474-481. https://doi.org/10.1016/j.jhep.2006.10.020
doi: 10.1016/j.jhep.2006.10.020
pubmed: 17239480
Vincenzi B, Di Maio M, Silletta M, D’Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G (2015) Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. 10 (7):e0133488. https://doi.org/10.1371/journal.pone.0133488
doi: 10.1371/journal.pone.0133488
Lencioni R, Montal R, Torres F, Park J-W, Decaens T, Raoul J-L, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang Y-K, Lim H-Y, Walters I, Llovet JM (2017) Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 66 (6):1166-1172. https://doi.org/10.1016/j.jhep.2017.01.012
doi: 10.1016/j.jhep.2017.01.012
pubmed: 28131794
Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, Pedrosa I, Khatri G, Yakoo T, Meyer JJ, Shaw J, Marrero JA, Singal AG (2014) Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome. Ann Surg Oncol 21 (4):1287-1295. https://doi.org/10.1245/s10434-013-3413-8
doi: 10.1245/s10434-013-3413-8
pubmed: 24318095
Llovet JM, Fuster J, Bruix J (2004) The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10 (S2):S115-S120. https://doi.org/10.1002/lt.20034
doi: 10.1002/lt.20034
pubmed: 14762851
Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA (2011) Chemoembolization Endpoints: Effect on Survival Among Patients With Hepatocellular Carcinoma. American Journal of Roentgenology 196 (4):919-928. https://doi.org/10.2214/ajr.10.4770
doi: 10.2214/ajr.10.4770
pubmed: 21427346
Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, King LY, Janas GL, Do RK, Kim CY, Ronald J, Bashir MR (2019) LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. Radiology 292 (1):226-234. https://doi.org/10.1148/radiol.2019182135
doi: 10.1148/radiol.2019182135
pubmed: 31038409
Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, Ronald J, Commander L, Hertel J, Luo S, Bashir MR, Burke LMB (2020) The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology 294 (2):320-326. https://doi.org/10.1148/radiol.2019191581
doi: 10.1148/radiol.2019191581
pubmed: 31845843
Kim SW, Joo I, Kim H-C, Ahn SJ, Kang H-J, Jeon SK, Lee JM (2020) LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol. https://doi.org/10.1007/s00330-019-06623-9
doi: 10.1007/s00330-019-06623-9
pubmed: 33241523
pmcid: 7880924
Thibodeau-Antonacci A, Petitclerc L, Gilbert G, Bilodeau L, Olivié D, Cerny M, Castel H, Turcotte S, Huet C, Perreault P, Soulez G, Chagnon M, Kadoury S, Tang A (2019) Dynamic contrast-enhanced MRI to assess hepatocellular carcinoma response to Transarterial chemoembolization using LI-RADS criteria: A pilot study. Magn Reson Imaging 62:78-86. https://doi.org/10.1016/j.mri.2019.06.017
doi: 10.1016/j.mri.2019.06.017
pubmed: 31247250
Seo N, Kim MS, Park M-S, Choi J-Y, Do RKG, Han K, Kim M-J (2019) Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Eur Radiol. https://doi.org/10.1007/s00330-019-06376-5
doi: 10.1007/s00330-019-06376-5
pubmed: 31748854
pmcid: 7485122
Zhang Y, Wang J, Li H, Zheng T, Jiang H, Li M, Song B (2020) Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation. Annals of Translational Medicine 8 (6):388-388. https://doi.org/10.21037/atm.2020.03.120
Davenport MS, Khalatbari S, Liu PSC, Maturen KE, Kaza RK, Wasnik AP, Al-Hawary MM, Glazer DI, Stein EB, Patel J, Somashekar DK, Viglianti BL, Hussain HK (2014) Repeatability of Diagnostic Features and Scoring Systems for Hepatocellular Carcinoma by Using MR Imaging. 272 (1):132-142. https://doi.org/10.1148/radiol.14131963
doi: 10.1148/radiol.14131963
Barth BK, Donati OF, Fischer MA, Ulbrich EJ, Karlo CA, Becker A, Seifert B, Reiner CS (2016) Reliability, Validity, and Reader Acceptance of LI-RADS—An In-depth Analysis. 23 (9):1145-1153. https://doi.org/10.1016/j.acra.2016.03.014
Yokoo T, Singal AG, Diaz De Leon A, Ananthakrishnan L, Fetzer DT, Pedrosa I, Khatri G (2020) Prevalence and clinical significance of discordant LI-RADS
doi: 10.1007/s00261-019-02133-w
pubmed: 31342103
Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 24 (4):965-973. https://doi.org/10.1093/annonc/mds605
doi: 10.1093/annonc/mds605
pubmed: 23223331
Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J (2013) Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. Hepatology 58 (6):2023-2031. https://doi.org/10.1002/hep.26586
doi: 10.1002/hep.26586
pubmed: 23787822
De La Torre-Aláez M, Jordán-Iborra C, Casadei-Gardini A, Bilbao JI, Rodriguez-Fraile M, Sancho L, D’Avola D, Herrero JI, Iñarrairaegui M, Sangro B (2020) The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. Cardiovasc Intervent Radiol. https://doi.org/10.1007/s00270-020-02444-2De La Torre-Aláez M, Jordán-Iborra C, Casadei-Gardini A, Bilbao JI, Rodriguez-Fraile M, Sancho L, D’Avola D, Herrero JI, Iñarrairaegui M, Sangro B (2020) The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. Cardiovasc Intervent Radiol. https://doi.org/10.1007/s00270-020-02444-2
doi: 10.1007/s00270-020-02444-2
pubmed: 32556607
Park S, Joo I, Lee DH, Bae JS, Yoo J, Kim SW, Lee JM (2020) Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI. Radiology 296 (3):554-561. https://doi.org/10.1148/radiol.2020192797
doi: 10.1148/radiol.2020192797
pubmed: 32692297
Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, Yaghmai V (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62 (4):1111-1121. https://doi.org/10.1002/hep.27915
doi: 10.1002/hep.27915
pubmed: 25999236
Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi J-I (2018) Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. Acad Radiol 25 (11):1363-1373. https://doi.org/10.1016/j.acra.2018.02.013
doi: 10.1016/j.acra.2018.02.013
pubmed: 29555570
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55 (6):1309-1316. https://doi.org/10.1016/j.jhep.2011.03.007
doi: 10.1016/j.jhep.2011.03.007
pubmed: 21703196
Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS (2013) Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 58 (6):1181-1187. https://doi.org/10.1016/j.jhep.2013.01.039
doi: 10.1016/j.jhep.2013.01.039
pubmed: 23395691